An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Rogaratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 21 Jun 2017 Planned End Date changed from 28 Feb 2018 to 30 Nov 2017.
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2017 Status changed from recruiting to active, no longer recruiting.